Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2003-03-11
2009-06-09
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093700
Reexamination Certificate
active
07544355
ABSTRACT:
The present invention relates, generally, to methods and compositions for allogeneic transplantation. More particularly, the invention relates to the use of alloreactive natural killer cells in order to enhance the efficacy and/or safety of allogeneic grafts in human subjects. The invention allows to increase the engraftment of an allogeneic grafts, even in myelo-reductive conditioning, to protect against GVHD and/or to eradicate malignant cells. The invention is particularly suited in allogeneic hematopoietic transplantations, particularly bone marrow transplantations.
REFERENCES:
patent: 6103694 (2000-08-01), Mardiney et al.
Ciccone et al, J Exp Med. Mar. 1, 1992;175:709-18.
Ruggeri et al, Curr Opin Hematol 2001;8:355-9.
Murphy et al, J Immunol 1992;148:2953-60.
Ruggeri et al, Transplant Immunol 2005;14:203-6.
Davies et al, Blood 2002;100:3825-7.
Malmberg et al., Mol Immunol 2005;42:531-4.
Asai, et al., Suppression of Graft-Versus-Host Disease and Amplification of Graft-Versus-Tumor Effects by Activated Natural Killer Cells after Allogeneic Bone Marrow Transplantation, The Journal of Clinical Investigation, vol. 101, No. 9, (May 1998), 1835-1842.
Ruggeri, et al., Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation, Blood, vol. 94, No. 1 (Jul. 1999), pp. 333-339.
Ruggeri, et al., Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants, Science, vol. 295, (Mar. 2002), pp. 2097-2100.
Ruggeri et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predicitve value. Blood, 2007; 110: 433-440.
Beelen DW, Hottinger HD, Ferencic S, et al. Genotypic Inhibitory Killer Immunoglobulin-like Receptor Ligand Incompatibility Enhances the Long-term Antileukemic Effect of Unmodified Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myeloid Leukemias. Blood 2005; 105:2594-2600.
Dawson MA and Spencer A. Successful use of haploidentical stem-cell transplantation with KIR mismatch as initial therapy for poor-risk myelodysplastic syndrome. J Clin Oncol 2005; 23:4473-4474.
Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102:814-819.
Elmaagacli AH, Ottinger H, Koldehoff M, et al. Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 2005; 79:1741-1747.
Kroger N, Shaw B, Iacobelli S, et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129:631-43.
Cooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106:4370-4376.
Igarashi et al, “Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells”, Blood 2004, vol. 104, No. 1, pp. 170-177.
Ruggeri et al, “Allogeneic hermatopoietic transplantation and natural killer cell recognition of missing self”, Immunological Reviews 2006, vol. 214, pp. 202-218.
Li Q. Janice
Nixon & Vanderhye P.C.
Universita Degli Studi di Perugia
LandOfFree
Methods and compositions for allogeneic transplantation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for allogeneic transplantation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for allogeneic transplantation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4136690